TOLREMO Raises CHF 9.0 Million in Series A and Strengthens Board of Directors

Zurich, September 24th 2018. TOLREMO therapeutics AG (“TOLREMO”), a privately held Swiss biotech company, announced today the completion of an oversubscribed series A financing round of CHF 9.0 million (USD $9.3 million). The Swiss venture capital firm BioMedPartners led the round and was joined by the Swiss venture capital firms Redalpine and Altos Venture, as well as TOLREMO’s existing shareholders including the Swiss bank Zürcher Kantonalbank and several experienced biotech investors. The capital increase will allow the ETH Spin-off to further advance two major drug development programs to prevent drug resistance in cancer therapies.

TOLREMO Raises CHF 2.4 Million in Seed Financing

Zurich, September 18th 2017. TOLREMO therapeutics AG (“TOLREMO”), a privately held research-stage biotechnology company, announced today the completion of a fundraiser with private investors of 2.4 million Swiss Francs. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.